MAPK9 and cancer: A series of 1,5-diarylpyrzole derivatives targeting EGFR and JNK-2 were developed and synthesized and biologically evaluated for their anticancer activity against a panel of five cancer cell lines, namely DLD-1, Hela, K562, SUIT-2, and HepG2.